Surrey Heartlands

Joint Formulary & PAD

Mepolizumab - Eosinophilic COPD

You are here : Home > Formulary Search > Mepolizumab - Eosinophilic COPD

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Injection
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
NICE
SPC
Restrictions / Comments :
Important

Awaiting implementation of service.

Documentation

Evidence Review
Mepolizumab NICE TA1166 Briefing paper - Sep 26

PAD Profile

ChemicalSubstance :
Mepolizumab
Indication :
Eosinophilic COPD
Group Name :
Keywords :
Brand Names Include :
Nucala
Important Information :

For maintenance treatment of uncontrolled COPD with raised blood eosinophils in line with NICE TA1166

Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Committee Recommendations (1)

01 Sep 26 - Surrey & Sussex Area Prescribing Committee (APC)

The Surrey & Sussex APC approved the use of mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils in line with NICE TA1166.

Other Indications

Below are listed other indications that Mepolizumab is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Eosinophilic COPD.

  • No records returned.